- Compugen (NASDAQ:CGEN) announces that a bispecific antibody of AstraZeneca (NASDAQ:AZN) derived from COM902, CGEN's anti-TIGIT antibody, will advance into clinical development.
- AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.
- COM902 was licensed to AstraZeneca in 2018 exclusively for the development of bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities.
- Under the license, AZN has the right to create multiple products. Compugen has received a $10M upfront payment and an additional $2M milestone payment to date, out of up to an aggregate milestone amount of $200M, as well as tiered royalties on future product sales.
- CGEN retained all other rights to its entire pipeline of programs as monotherapies and in combination with other products.